Nicole DeFeudis Editor Bausch + Lomb and Novaliq secured an approval for their dry eye disease drop on Thursday, to be marketed as Miebo. The drug, also known as perfluorohexyloctane ophthalmic solution or previously NOV03, targets tear evaporation, a leading cause of dry eye disease. Bausch + Lomb CEO Brent Saunders expects the drug to...